Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation

Yasushi Hiramatsu, Yoshinobu Maeda, Nobuharu Fujii, Takashi Saito, Yuichiro Nawa, Masamichi Hara, Tomofumi Yano, Shoji Asakura, Kazutaka Sunami, Takayuki Tabayashi, Akira Miyata, Ken-ichi Matsuoka, Katsuji Shinagawa, Kazuma Ikeda, Keitaro Matsuo, Mitsune Tanimoto

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

A prospective randomized clinical trial assessed the efficacy and tolerance of micafungin compared with that of standard fluconazole treatment in patients undergoing hematopoietic stem cell transplantation (HSCT). Adult patients (n = 106) were randomly assigned to receive prophylaxis with either micafungin 150 mg (n = 52), or fluconazole 400 mg (n = 52). Success was defined as the absence of suspected, proven, or probable invasive fungal infection (IFI) through the end of therapy and the absence of proven or probable IFI through the end of the 4-week period following treatment. The overall efficacy of micafungin was comparable to that of fluconazole (94 vs. 88%; difference 6.0%; 95% confidence interval, -5.4 to +17.4%; P = 0.295). A total of 2 (4.0%) of 50 patients in the micafungin arm and 6 (12.0%) of 50 patients in the fluconazole arm received empirical antifungal therapy (P = 0.06). Micafungin treatment did not result in increasing adverse effects and had a safe profile as fluconazole in neutropenic patients. This randomized trial indicates that the efficacy and tolerance of micafungin 150 mg was comparable to that of fluconazole 400 mg, suggesting that micafungin at 150 mg daily represents a valuable new treatment option for antifungal prophylaxis in HSCT recipients.

Original languageEnglish
Pages (from-to)588-595
Number of pages8
JournalInternational Journal of Hematology
Volume88
Issue number5
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Fluconazole
Hematopoietic Stem Cell Transplantation
Therapeutics
micafungin
Randomized Controlled Trials
Confidence Intervals

Keywords

  • Antifungal prophylaxis
  • Hematopoietic stem cell transplantation
  • Micafungin

ASJC Scopus subject areas

  • Hematology

Cite this

Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. / Hiramatsu, Yasushi; Maeda, Yoshinobu; Fujii, Nobuharu; Saito, Takashi; Nawa, Yuichiro; Hara, Masamichi; Yano, Tomofumi; Asakura, Shoji; Sunami, Kazutaka; Tabayashi, Takayuki; Miyata, Akira; Matsuoka, Ken-ichi; Shinagawa, Katsuji; Ikeda, Kazuma; Matsuo, Keitaro; Tanimoto, Mitsune.

In: International Journal of Hematology, Vol. 88, No. 5, 12.2009, p. 588-595.

Research output: Contribution to journalArticle

Hiramatsu, Y, Maeda, Y, Fujii, N, Saito, T, Nawa, Y, Hara, M, Yano, T, Asakura, S, Sunami, K, Tabayashi, T, Miyata, A, Matsuoka, K, Shinagawa, K, Ikeda, K, Matsuo, K & Tanimoto, M 2009, 'Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation', International Journal of Hematology, vol. 88, no. 5, pp. 588-595. https://doi.org/10.1007/s12185-008-0196-y
Hiramatsu, Yasushi ; Maeda, Yoshinobu ; Fujii, Nobuharu ; Saito, Takashi ; Nawa, Yuichiro ; Hara, Masamichi ; Yano, Tomofumi ; Asakura, Shoji ; Sunami, Kazutaka ; Tabayashi, Takayuki ; Miyata, Akira ; Matsuoka, Ken-ichi ; Shinagawa, Katsuji ; Ikeda, Kazuma ; Matsuo, Keitaro ; Tanimoto, Mitsune. / Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. In: International Journal of Hematology. 2009 ; Vol. 88, No. 5. pp. 588-595.
@article{af697fd73b5c43249915e9cca10e4e9b,
title = "Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation",
abstract = "A prospective randomized clinical trial assessed the efficacy and tolerance of micafungin compared with that of standard fluconazole treatment in patients undergoing hematopoietic stem cell transplantation (HSCT). Adult patients (n = 106) were randomly assigned to receive prophylaxis with either micafungin 150 mg (n = 52), or fluconazole 400 mg (n = 52). Success was defined as the absence of suspected, proven, or probable invasive fungal infection (IFI) through the end of therapy and the absence of proven or probable IFI through the end of the 4-week period following treatment. The overall efficacy of micafungin was comparable to that of fluconazole (94 vs. 88{\%}; difference 6.0{\%}; 95{\%} confidence interval, -5.4 to +17.4{\%}; P = 0.295). A total of 2 (4.0{\%}) of 50 patients in the micafungin arm and 6 (12.0{\%}) of 50 patients in the fluconazole arm received empirical antifungal therapy (P = 0.06). Micafungin treatment did not result in increasing adverse effects and had a safe profile as fluconazole in neutropenic patients. This randomized trial indicates that the efficacy and tolerance of micafungin 150 mg was comparable to that of fluconazole 400 mg, suggesting that micafungin at 150 mg daily represents a valuable new treatment option for antifungal prophylaxis in HSCT recipients.",
keywords = "Antifungal prophylaxis, Hematopoietic stem cell transplantation, Micafungin",
author = "Yasushi Hiramatsu and Yoshinobu Maeda and Nobuharu Fujii and Takashi Saito and Yuichiro Nawa and Masamichi Hara and Tomofumi Yano and Shoji Asakura and Kazutaka Sunami and Takayuki Tabayashi and Akira Miyata and Ken-ichi Matsuoka and Katsuji Shinagawa and Kazuma Ikeda and Keitaro Matsuo and Mitsune Tanimoto",
year = "2009",
month = "12",
doi = "10.1007/s12185-008-0196-y",
language = "English",
volume = "88",
pages = "588--595",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation

AU - Hiramatsu, Yasushi

AU - Maeda, Yoshinobu

AU - Fujii, Nobuharu

AU - Saito, Takashi

AU - Nawa, Yuichiro

AU - Hara, Masamichi

AU - Yano, Tomofumi

AU - Asakura, Shoji

AU - Sunami, Kazutaka

AU - Tabayashi, Takayuki

AU - Miyata, Akira

AU - Matsuoka, Ken-ichi

AU - Shinagawa, Katsuji

AU - Ikeda, Kazuma

AU - Matsuo, Keitaro

AU - Tanimoto, Mitsune

PY - 2009/12

Y1 - 2009/12

N2 - A prospective randomized clinical trial assessed the efficacy and tolerance of micafungin compared with that of standard fluconazole treatment in patients undergoing hematopoietic stem cell transplantation (HSCT). Adult patients (n = 106) were randomly assigned to receive prophylaxis with either micafungin 150 mg (n = 52), or fluconazole 400 mg (n = 52). Success was defined as the absence of suspected, proven, or probable invasive fungal infection (IFI) through the end of therapy and the absence of proven or probable IFI through the end of the 4-week period following treatment. The overall efficacy of micafungin was comparable to that of fluconazole (94 vs. 88%; difference 6.0%; 95% confidence interval, -5.4 to +17.4%; P = 0.295). A total of 2 (4.0%) of 50 patients in the micafungin arm and 6 (12.0%) of 50 patients in the fluconazole arm received empirical antifungal therapy (P = 0.06). Micafungin treatment did not result in increasing adverse effects and had a safe profile as fluconazole in neutropenic patients. This randomized trial indicates that the efficacy and tolerance of micafungin 150 mg was comparable to that of fluconazole 400 mg, suggesting that micafungin at 150 mg daily represents a valuable new treatment option for antifungal prophylaxis in HSCT recipients.

AB - A prospective randomized clinical trial assessed the efficacy and tolerance of micafungin compared with that of standard fluconazole treatment in patients undergoing hematopoietic stem cell transplantation (HSCT). Adult patients (n = 106) were randomly assigned to receive prophylaxis with either micafungin 150 mg (n = 52), or fluconazole 400 mg (n = 52). Success was defined as the absence of suspected, proven, or probable invasive fungal infection (IFI) through the end of therapy and the absence of proven or probable IFI through the end of the 4-week period following treatment. The overall efficacy of micafungin was comparable to that of fluconazole (94 vs. 88%; difference 6.0%; 95% confidence interval, -5.4 to +17.4%; P = 0.295). A total of 2 (4.0%) of 50 patients in the micafungin arm and 6 (12.0%) of 50 patients in the fluconazole arm received empirical antifungal therapy (P = 0.06). Micafungin treatment did not result in increasing adverse effects and had a safe profile as fluconazole in neutropenic patients. This randomized trial indicates that the efficacy and tolerance of micafungin 150 mg was comparable to that of fluconazole 400 mg, suggesting that micafungin at 150 mg daily represents a valuable new treatment option for antifungal prophylaxis in HSCT recipients.

KW - Antifungal prophylaxis

KW - Hematopoietic stem cell transplantation

KW - Micafungin

UR - http://www.scopus.com/inward/record.url?scp=64249152006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64249152006&partnerID=8YFLogxK

U2 - 10.1007/s12185-008-0196-y

DO - 10.1007/s12185-008-0196-y

M3 - Article

C2 - 19039629

AN - SCOPUS:64249152006

VL - 88

SP - 588

EP - 595

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 5

ER -